Role of plasma lipoproteins in modifiying the toxic effects of water-insoluble drugs: Studies with cyclosporine A

AAPS PharmSci

Volumn 4, Issue 4, 2002, Pages

  Wasan, Kishor M ^a   Ramaswamy, Manisha ^a   Kwong, Mona ^a   Boulanger, Kathy D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cholesterol; Cholesteryl ester; Cyclosporine; Lipoprotein receptors; Lipoproteins; Low density; Transfer protein

Indexed keywords

CARRIER PROTEIN; CYCLOSPORIN A; LIPID; LIPID TRANSFER PROTEIN; LIPOPROTEIN; LIPOPROTEIN RECEPTOR; WATER; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER; CARDIOVASCULAR SYSTEM; CHEMICAL COMPOSITION; DIABETES MELLITUS; DRUG SOLUBILITY; DRUG UPTAKE; EXTRAVASCULAR FLUID; HUMAN; HYDROPHOBICITY; LIPID ABSORPTION; LIPID TRANSPORT; LIPOGENESIS; LIPOPROTEIN BLOOD LEVEL; MACROMOLECULE; NEPHROTOXICITY; REVIEW; TISSUE REPAIR; ANIMAL; BLOOD; CHEMISTRY; METABOLISM; SOLUBILITY;

ANIMALS; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIPOPROTEINS; SOLUBILITY; WATER;

EID: 52449094242     PISSN: 15221059     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Davis RA. Lipoprotein structure and function In: Biochemistry of Lipids, Lipoproteins and Membranes. ed. DE Vance and JE Vance, New York, NY: Elsevier; 1996:403-426.
2. Wasan KM, Cassidy SM. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J Pharm Sci. 1998;87:411-424.
3. Bennett WM. Renal effects of cyclosporine. J Am Acad Dermatol. 1990;23:1280-1287.
4. Awni WM, Sawchuk RJ. The pharmacokinetics of cyclosporine, II: blood plasma distribution and binding studies. Drug Metab Dispos. 1985;13:133-138.
5. Wasan KM, Pritchard PH, Ramaswamy M, Wong W, Donnachie EM, Brunner LJ. Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine. Pharm Res. 1997;14:1613-1620.
6. de Kippel N, Sennesael J, Lamote J, Ebinger G, de Keyser J. Cyclosporin leukoencephalopathy induced by intravenous lipid solution. Lancet. 1992;339:1114-1115.
7. de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RA. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med. 1987;317:861-866.
8. Gardier AM, Mathe D, Guedeney X, et al. Effects of plasma lipid levels on blood distribution and pharmacokinetics of cyclosporin A. Ther Drug Monit. 1993;15:274-280.
9. Lemaire M, Pardridge WM, Chaudhuri G. Influence of blood components on the tissue uptake indices of cyclosporin in rats. J Pharm Exp Ther. 1988;244:740-743.
10. Pardridge WM. Carrier-mediated transport of thyroid hormones through the rat blood-brain barrier: primary role of albumin-bound hormone. Endocrinol. 1979;105:605-612.
11. Arnadottir M, Thysell H, Nilsson-Ehle P. Lipoprotein levels and post-heparin lipase activities in kidney transplant recipients: ciclosporin- versus non-ciclosporin-treated patients. Am J Nephrol. 1991;11:391-396.
12. Drayna D, Jarnagin AS, McLean J, et al. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature. 1987;327:632-634.
13. Hesler CB, Swenson TL, Tall AR. Purification and characterization of a human plasma cholesteryl ester transfer protein. J Biol Chem. 1987;262:2275-2282.
14. Schumann RR, Leong SR, Flaggs GW, et al. Structure and function of lipopolysaccharide binding protein. Science. 1990;249:1429-1431.
15. Ha YC, Barter PJ. Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp Biochem Physiol. 1982;B71(2):265-269.
16. Lagrost L. Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. Biochim Biophys Acta. 1994;1215(3):209-236.
17. Moulin P. Cholesteryl ester transfer protein: an enigmatic protein. Horm Res. 1996;45 (3-5):238-244.
18. Morton RE, Zilversmit DB. Purification and characterization of lipid transfer protein(s) from human lipoprotein-deficient plasma. J Lipid Res. 1982;23(7):1058-1067.
19. Morton RE, Zilversmit DB. Inter-relationship of lipids transferred by the lipid-transfer protein isolated from human lipoprotein-deficient plasma. J Biol Chem. 1983;258 (19):11751-11757.
20. Tall AR, Forester LR, Bongiovanni GL. Facilitation of phosphatidylcholine transfer into high density lipoproteins by an apolipoprotein in the density 1.20-1.26 g/ml fraction of plasma. J Lipid Res. 1983;24(3):277-289.
21. Morton RE. Interaction of lipid transfer protein with plasma lipoproteins and cell membranes. Experientia. 1990;46(6):552-560.
22. Tall A. Plasma lipid transfer proteins. Annu Rev Biochem. 1995;64:235-257.
23. Wasan KM, Ramaswamy M, Wong W, Pritchard PH. Lipid transfer protein I facilitated transfer of cyclosporine from low- to high-density lipoproteins is only partially dependent on its cholesteryl ester transfer activity. J Pharmacol Exp Ther. 1998;284:599-605.
24. Hughes TA, Gaber AO, Montgomery CE. Plasma distribution of cyclosporine within lipoproteins and "in vitro" transfer between very-low-density lipoproteins, low-density lipoproteins, and high-density lipoproteins. Ther Drug Monit. 1991;13(4):289-295.
25. Wasan KM, Grossie VB Jr, Lopez-Berestein G. Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion. Antimicrob Agents Chemother. 1994;38:2224-2226.
26. de Groen PC. Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clin Proc. 1988;63:1012-1021.
27. Rifai N, Chao FF, Pham Q, Thiessen J, Soldin SJ. The role of lipoproteins in the transport and uptake of cyclosporine and dihydro-tacrolimus into HepG2 and JURKAT cell lines. Clin Biochem. 1996;29:149-155.
28. Peteherych KD, Wasan KM. Effects of plasma lipoproteins on cyclosporine A toxicity and uptake in LLC PK1 pig kidney cells. J Pharm Sci. 2001;90:1395-1406.